Lordick Florian, Al-Batran Salah-Eddin, Dietel Manfred, Gaiser Timo, Hofheinz Ralf-Dieter, Kirchner Thomas, Kreipe Hans H, Lorenzen Sylvie, Möhler Markus, Quaas Alexander, Röcken Christoph, Rüschoff Josef, Tannapfel Andrea, Thuss-Patience Peter, Baretton Gustavo
Universitätsklinikum Leipzig, Universitäres Krebszentrum (UCCL), Liebigstraße 20, 04103, Leipzig, Germany.
UCT University Cancer Center Frankfurt, Frankfurt am Main, Germany.
J Cancer Res Clin Oncol. 2017 May;143(5):835-841. doi: 10.1007/s00432-017-2374-x. Epub 2017 Mar 11.
Valid HER2 testing is essential for optimal therapy of patients with HER2-positive gastric cancer and the correct use of first-line chemotherapy. While testing for HER2 status in breast cancer is routinely performed, this is not the case for HER2 testing in gastric cancer and it is usually only performed on clinician request. An interdisciplinary German expert group (pathologists and clinicians) took the challenges of HER2 testing in gastric cancer as an opportunity to address essential aspects and questions for the practical use of HER2 testing in this indication. The recommendations made in this manuscript reflect the consensus of all participants and reflect their opinions and long-term experience in this field.
有效的HER2检测对于HER2阳性胃癌患者的最佳治疗以及一线化疗的正确使用至关重要。虽然乳腺癌中HER2状态检测是常规进行的，但在胃癌中并非如此，HER2检测通常仅在临床医生要求时才进行。一个跨学科的德国专家组（病理学家和临床医生）将胃癌中HER2检测面临的挑战作为契机，来探讨该检测在这一适应症实际应用中的关键方面和问题。本手稿中提出的建议反映了所有参与者的共识，并体现了他们在该领域的观点和长期经验。
